化合物RD162 T21740

Product Introduction
Bioactivity


英文名: RD162

描述: RD162 是一种与雄激素受体 (AR) 特异性结合的非甾体抗雄激素 (NSAA)。

体外活性: RD162对黄体酮、雌激素或糖皮质激素受体的结合力微乎其微。在含有内源性AR基因扩增的人类前列腺癌细胞系VCaP中，RD162（1-10 μM）抑制细胞生长并诱导细胞凋亡[1]。

体内活性: RD162 (20 mg/kg) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours. RD162 (10 mg/kg; oral gavage) causes all tumors regressed. RD162 (0.1, 1, 10 mg/kg; oral gavage) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (104.94 mM)


关键字: inhibit | prostate | RD162 | Androgen Receptor | VCaP | Inhibitor | castration | RD 162 | NSAA | RD-162 | LNCaP | diarylthiohydantoin | orally

相关产品: p,p'-DDE | WCA-814 | Enzalutamide carboxylic acid | Lupeol | Bavdegalutamide | ARD-1676 | S-23 | Flutamide | Cyproterone acetate | CTK8A3536

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | Anti-Prostate Cancer Compound Library | Transcription Factor-Targeted Compound Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Nuclear Receptor Compound Library | Anti-Cancer Approved Drug Library | Target-Focused Phenotypic Screening Library

化合物RD162 T21740信息由TargetMol中国为您提供，如您想了解更多关于化合物RD162 T21740报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途